Quick Answer
aTYR PHARMA INC reported Operating Income Loss of -$77.63 million for the year ending 2025.
- aTYR PHARMA INC showed a decrease of -14.3% in Operating Income Loss from 2024 to 2025.
- This data is from aTYR PHARMA INC's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), aTYR PHARMA INC's Operating Income Loss has declined by 297.2%.
- Historical annual values: Fiscal year 2025: -$77.63 million | Fiscal year 2024: -$67.91 million | Fiscal year 2023: -$54.92 million | Fiscal year 2022: -$46.40 million | Fiscal year 2021: -$34.02 million | Fiscal year 2020: -$15.91 million | Fiscal year 2019: -$22.98 million | Fiscal year 2018: -$32.82 million | Fiscal year 2017: -$47.15 million | Fiscal year 2016: -$57.94 million | Fiscal year 2015: -$47.62 million | Fiscal year 2014: -$23.55 million | Fiscal year 2013: -$19.54 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: